TME Clinical Trials in Beijing, Beijing Municipality
17 recruitingBeijing, Beijing Municipality, China
Showing 1–17 of 17 trials
Recruiting
Not Applicable
Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial
StrokeICAD - Intracranial Atherosclerotic DiseaseICAS - Intracranial Atherosclerosis+3 more
Beijing Tiantan Hospital358 enrolled18 locationsNCT04948749
Recruiting
China Research for Severe Spontaneous Intracerebral Hemorrhage（CRISIH）
Emergency surgeryComplicationsDisorders of Consciousness+2 more
Beijing Tiantan Hospital2,000 enrolled1 locationNCT05975398
Recruiting
Not Applicable
Efficacy of Bright Light Therapy on Cognitive Impairment in Major Depressive Disorder and Its Neuroimaging Mechanisms: Protocol for a Randomised Controlled Trial
Cognitive ImpairmentMajor Depressive Disorder (MDD)Neuroimaging+1 more
Peking University Sixth Hospital120 enrolled2 locationsNCT07508215
Recruiting
Phase 1
Zorifertinib With Osimertinib for NSCLC With Meningeal Progression
Patients With Advanced Non-small Cell Lung Cancer With Meningeal Progression After Osimertinib Treatment
Alpha Biopharma (Jiangsu) Co., Ltd.42 enrolled5 locationsNCT07361705
Recruiting
Phase 2
A Phase II Clinical Trial of the Safety and Efficacy of SAL056 at Different Doses and Dosing Regimens
postmenopausal women with osteoporosis
Shenzhen Salubris Pharmaceuticals Co., Ltd.200 enrolled1 locationNCT07579936
Recruiting
Phase 3
Intra-arterial Tenecteplase for Acute Medium Vessel Occlusion Stroke
Ischemic StrokeMedium Vessel OcclusionEndovascular Treatment+1 more
Beijing Tiantan Hospital488 enrolled1 locationNCT07357987
Recruiting
Phase 3
Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer
First-line Treatment of Metastatic Pancreatic Cancer
Jiangsu HengRui Medicine Co., Ltd.662 enrolled1 locationNCT07238283
Recruiting
The Efficacy and Safety of PEGylated GH for the Treatment of Short Stature in Chinese Children-GLOBE Reg
Growth DisordersGrowth Hormone Treatment
Beijing Children's Hospital2,600 enrolled1 locationNCT06037473
Recruiting
Phase 3
A Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB - IIIB NSCLC With Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations, Following Complete Surgical Resection With or Without Adjuvant Chemotherapy（FIRMOST）
NSCLCAdjuvant Treatment
Allist Pharmaceuticals, Inc.338 enrolled2 locationsNCT07010419
Recruiting
Phase 2Phase 3
The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical Study
HER2-positive Breast CancerPyrotinib Treatment
Cancer Institute and Hospital, Chinese Academy of Medical Sciences964 enrolled1 locationNCT06958627
Recruiting
Safety and Efficacy of Edoxaban and Rivaroxaban to Cerebral Venous Thrombosis in Chinese Patients
Anticoagulant TherapyCerebral Venous ThrombosisAnticoagulant Drugs+6 more
Xuanwu Hospital, Beijing1,486 enrolled1 locationNCT06947707
Recruiting
Not Applicable
Liquid Biopsy-Based Novel Modality for Postoperative Management of Lung Cancer
Non-small Cell Lung CancerMinimal Residual DiseaseAdaptive Treatment
Peking University People's Hospital1,000 enrolled1 locationNCT06930807
Recruiting
Phase 3
HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer
First-line Treatment of Advanced Pancreatic Cancer
Jiangsu HengRui Medicine Co., Ltd.778 enrolled1 locationNCT05751850
Recruiting
Phase 4
Efficacy Safety BaiDiZiYin ShenQiYiFei Adjunctive Treatments Pulmonary Tuberculosis
TreatmentAdjuvantTuberculosis
Beijing Chest Hospital292 enrolled1 locationNCT06403943
Recruiting
A Study on Diagnosis and Treatment Strategies for Atlantoaxial Dislocation
TreatmentAtlantoaxial DislocationDiagnostic
Peking University Third Hospital3,000 enrolled1 locationNCT06233539
Recruiting
Clinical Study of Individualized Treatment of Relapsed or Drug-resistant Advanced Gynecological Tumors Guided by PTC Model
Personalized Cancer Treatment
Hua Li40 enrolled1 locationNCT06232213
Recruiting
Phase 3
A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma
Treatment-naїve Mantle Cell Lymphoma
Beijing InnoCare Pharma Tech Co., Ltd.356 enrolled22 locationsNCT05051891